Previous close | 0.4187 |
Open | 0.4260 |
Bid | 0.4197 x 200 |
Ask | 0.4437 x 200 |
Day's range | 0.4221 - 0.4339 |
52-week range | 0.2570 - 3.2800 |
Volume | |
Avg. volume | 625,664 |
Market cap | 13.827M |
Beta (5Y monthly) | 3.46 |
PE ratio (TTM) | 0.11 |
EPS (TTM) | 4.0000 |
Earnings date | 10 Jun 2024 - 14 Jun 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 760.00 |
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the first patient has been enrolled in the Austere environments Consortium for Enhanced Sepsis Outcomes' (ACESO) U.S. government-supported PROTECT multinational platform trial for early COVID-19 outpatient treatment. RHB-107 (upamostat) is the first drug being tested in this platform study. Funded through non-dilutive external sources, including the U.S. Department of D
RedHill Biopharma ( NASDAQ:RDHL ) Full Year 2023 Results Key Financial Results Net income: US$23.9m (up from US$71.7m...
RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today reported its full year 2023 financial results and operational highlights and associated filing of its annual report on Form 20-F for the year ended December 31, 2023.